APO-CLOPIDOGREL 300 MG
CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 300 MG · DIN 02398591 · APOTEX INC
Health Canada status: MARKETED
What is APO-CLOPIDOGREL?
APO-CLOPIDOGREL 300 MG contains CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02398591, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Jan-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CLOPIDOGREL used for?
Secondary prevention of atherothrombotic events in patients with atherosclerosis (stroke, MI, PAD); Acute Coronary Syndrome (with ASA); Atrial Fibrillation (with ASA) in specific patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02398591 |
|---|---|
| Brand name | APO-CLOPIDOGREL |
| Generic / active ingredient | CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 300 MG |
| Manufacturer | APOTEX INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AC04 CLOPIDOGREL |
| AHFS class | 20:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jan-2013 |
| Original market date | 2013-01-21 00:00:00 |
How is it administered?
75 mg once daily for MI/Stroke/PAD. ACS: 300 mg loading dose then 75 mg daily with ASA. Atrial Fibrillation: 75 mg daily with ASA. Oral use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though typically 15-30°C for such products.
How is it supplied?
75 mg: Blisters of 30, bottles of 100 and 500. 300 mg: Blisters of 30, bottles of 100.
Contraindications
Hypersensitivity to drug/ingredients; active bleeding (e.g., peptic ulcer, intracranial hemorrhage); significant liver impairment or cholestatic jaundice; concomitant use of repaglinide.
Warnings and precautions
CYP2C19 poor metabolisers have diminished response. Increased risk of bleeding; TTP reported rarely. Cross-reactivity among thienopyridines may occur. Contains lactose.
Is CLOPIDOGREL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B01AC04 CLOPIDOGREL. 19 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CLOPIDOGREL | 75 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02431971 |
| APO-CLOPIDOGREL | 75 MG | TABLET | APOTEX INC | MARKETED | DIN 02252767 |
| AURO-CLOPIDOGREL | 75 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02416387 |
| BIO-CLOPIDOGREL | 75 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444895 |
| CLOPIDOGREL | 75 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385813 |
| CLOPIDOGREL | 75 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02394820 |
| CLOPIDOGREL | 75 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02400553 |
| JAMP-CLOPIDOGREL | 75 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02415550 |
| M-CLOPIDOGREL | 75 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02502283 |
| MAR-CLOPIDOGREL | 75 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02422255 |
Who else supplies CLOPIDOGREL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLOPIDOGREL appears in 321 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.